Peter Wehrwein


COVID-19 and Cancer: NCI's Sharpless Says COVID-19 Could Halt Streak of US Cancer Mortality Gains

July 19, 2020

The talk by Ned Sharpless, MD, director of the National Cancer Institute, preceded presentations on some of the earliest findings about the effects of COVID-19 on cancer: It appears that patients treated with chemotherapy for lung or thoracic cancer shortly before being diagnosed with COVID-19 face a higher risk of death, and so do patients with cancer who take the combination of hydroxychloroquine (HCQ) and azithromycin.

Apixaban, Dalteprin Shown to Have Same Bleeding Risk in Patients With Cancer

March 29, 2020

Results of a study comparing apixaban with low-molecular-weight heparin as a treatment to prevent recurrent blood clots in patients with cancer may assuage some of the concern about the bleeding risk associated with direct-acting oral anticoagulants.